Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allo-HCT for Low Grade B-Cell Malignancies
NCT00714259Phase 3Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2008
- Primary completion
- Feb 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic hematopoietic stem cells in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL), Waldenstrom macroglobulinemia (WM), sponsored by University of Alabama at Birmingham. Started Jul 2008; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00714259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00714259.